“This dosing regimen patent reflects our commitment to enhancing our intellectual property portfolio,” said Brian Sullivan, CEO and Co-Founder of Celcuity. “With patent exclusivity for gedatolisib now ...

The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival ...